Emyrus Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 03-11-2024
- Paid Up Capital ₹ 0.10 M
as on 03-11-2024
- Company Age 4 Year, 6 Days
- Last Filing with ROC 31 Mar 2023
- Revenue -21.88%
(FY 2023)
- Profit 191.87%
(FY 2023)
- Ebitda 155.37%
(FY 2023)
- Net Worth 976.66%
(FY 2023)
- Total Assets -86.36%
(FY 2023)
About Emyrus Biotech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nimish Thakkar and Shailesh Shetty serve as directors at the Company.
- CIN/LLPIN
U74999MH2021PTC353257
- Company No.
353257
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jan 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Emyrus Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shailesh Shetty  | Director | 09-Jan-2021 | Current |
| Nimish Thakkar | Director | 09-Jan-2021 | Current |
Financial Performance of Emyrus Biotech.
Emyrus Biotech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 21.88% decrease. The company also saw a substantial improvement in profitability, with a 191.87% increase in profit. The company's net worth Soared by an impressive increase of 976.66%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emyrus Biotech?
In 2023, Emyrus Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kreative Friends Consultancy Services Private LimitedActive 12 years 1 monthShailesh Shetty is a mutual person
Zuvius Lifesciences Private LimitedActive 19 years 4 monthsNimish Thakkar and Shailesh Shetty are mutual person
- Mecobots Private LimitedActive 6 years 3 months
Nimish Thakkar and Shailesh Shetty are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Emyrus Biotech?
Emyrus Biotech has a workforce of 0 employees as of Apr 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emyrus Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emyrus Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
